Xeris Biopharma Holdings (XERS) closed out FY 2025 with fourth quarter revenue of US$85.8 million, basic EPS of US$0.07, and net income of US$11.1 million. On a trailing twelve month basis, revenue was US$291.8 million and basic EPS was US$0.00, reflecting a small net profit of US$0.6 million. The company has seen revenue move from US$203.1 million and basic EPS of a US$0.37 loss on a trailing basis in Q4 2024 to US$291.8 million and essentially breakeven EPS by Q4 2025. That shift toward profitability sets up a story focused squarely on how durable these improving margins might be.

See our full analysis for Xeris Biopharma Holdings.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the widely followed narratives around Xeris, highlighting where the story is supported by the data and where it is being challenged.

Profitability Arrives, But Interest Still Bites

• On a trailing 12 month view, Xeris earned US$0.6 million of net income on US$291.8 million of revenue, just enough to move into the black while risk data still highlight that interest payments are not well covered by these earnings.
• Critics focused on the bearish narrative point out rising R&D and commercial spend and warn that this could prolong weak net margins. However, the shift from a trailing loss of US$54.8 million in Q4 2024 to a small trailing profit in Q4 2025 shows the current cost base is at least supporting break even results.
• The bearish view flags cash flow strain from heavy investment, while the latest annual numbers show revenue of US$291.8 million already covering operating costs well enough to avoid another year of sizeable losses.
• Bears also worry that higher financing costs could weigh on results, which is consistent with the risk flag on interest coverage, so the new profitability level still sits on a relatively thin cushion.

Revenue Near US$292m Meets Growth Story

• Trailing 12 month revenue reached US$291.8 million compared with US$203.1 million a year earlier, alongside data indicating revenue growth of about 16.3% per year and forecasts that outpace the wider US market.
• Supporters of the bullish narrative argue that strong demand for key drugs like Recorlev, Gvoke, and Keveyis can push revenues higher. The move from US$187.4 million of trailing revenue in Q3 2024 to US$291.8 million in Q4 2025 backs the idea that the core portfolio is already scaling into a larger top line.
• Bullish investors also cite the opportunity in underserved endocrine markets, and the roughly US$104 million increase in trailing revenue over five quarters shows that existing products are already reaching more patients.
• At the same time, bears highlight dependence on a limited set of therapies, so this revenue climb still comes from a concentrated base that would be sensitive to any slowdown in those drugs.

Have bulls got this profit and revenue ramp right, or are expectations getting ahead of the FY 2025 numbers you are seeing here? 🐂 Xeris Biopharma Holdings Bull Case

US$6.02 Price Versus DCF And Risk Flags

• At a share price of US$6.02, Xeris is flagged as trading on a P/S of 3.4x versus peer and industry averages of 4.7x and 4.2x, and below a DCF fair value of US$42.98, while the same dataset calls out weak interest coverage and recent insider selling as key risks.
• Skeptics in the bearish camp point to that interest coverage issue and the insider selling as signs that the low P/S and wide gap to the DCF fair value may reflect financing and execution risks, even though the company has just reported trailing profitability and revenue of US$291.8 million.
• The bearish narrative argues that heavy spending and competition could limit future earnings, and if that happens the current P/S of 3.4x might not look unusually low relative to peers.
• On the other hand, the combination of a small trailing profit and a DCF fair value of US$42.98 against a US$6.02 price creates a large valuation gap that bears need to justify with those same risk factors.

If you are weighing that low sales multiple against the debt and insider selling flags, it can help to see how a cautious view pieces the data together. 🐻 Xeris Biopharma Holdings Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xeris Biopharma Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing the bullish and bearish arguments, do you feel the market is too cautious or too optimistic here? Act while the details are fresh and review the full spread of 4 key rewards and 2 important warning signs to shape your own view.

Explore Alternatives

For all the progress toward breakeven, Xeris still faces thin net margins, weak interest coverage, and insider selling that keeps financing risk firmly on the radar.

If that mix of fragile profitability and debt concerns makes you uneasy, check out 76 resilient stocks with low risk scores to quickly focus on companies with more resilient financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.